The global Peptide Drug Conjugates market is anticipated to hold a market value of USD 861.12 Million in 2023 and USD 5,331.83 Million by 2033. The projected growth rate is nearly 20% during the forecast period from 2023 to 2033.
The robust clinical trial pipeline with peptide drug conjugates (PDCs) coupled with an increase in Research and Development investments for developing PDCs and the rising disease burden across the globe are the factors expected to contribute to the market growth. For instance, in July 2021, Takeda Pharmaceutical Company Limited in collaboration with Peptide Dream announced investing USD 3.5 billion to develop peptide drugs for neuromuscular disease.
| Report Attributes | Details |
|---|---|
| Estimated Market Value in 2023 | USD 861.12 Million |
| Estimated Market Value in 2033 | USD 5,331.83 Million |
| Projected CAGR from 2023 to 2033 | 20% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global peptide drug conjugates market garnered USD 717.6 Million in 2022, expanding at a historical CAGR of 16%. Pharmaceutical companies are developing PDCs for metabolic diseases and coronavirus diseases and cancer among others.
Currently, the market has two FDA-approved drugs Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. Therefore, the rising prevalence of such diseases is driving the peptide drug conjugates market. According to the National Cancer Institute, in 2020, more than 1.8 million new cancer cases and more than 600,000 deaths occurred in the USA due to cancer.
Due to the increased number of cancer cases, the pharmaceutical industry has been pushed to investigate additional drug conjugates, resulting in the development and popularity of PDCs. The estimation reveals that the PDCs market is projected to secure a market value of USD 5,331.83 Million by 2033.
Growing Technological Advancements and Financial Investments to Aid Market Growth
The strong product pipeline and increasing financial investments in research and development are offering lucrative opportunities for the peptide drug conjugates market growth. For instance, AngioChem, Inc.’s product candidate- ANG1005 indicated for brain tumors is undergoing phase 3 clinical studies, and Bicycle Therapeutics pipeline products- BT5528&BT1718 indicated for non-small cell carcinoma, are under phase 2 clinical trials. Hence, the expected new PDC approval for the treatment of multiple types of cancer will boost the market growth in the near future.
According to the national cancer institute, there are more than 250 FDA-approved chemotherapeutic drugs used in the treatment of malignant tumors. However, the major drawback associated with such small molecules is uncontrolled toxicity resulting in severe side effects. Moreover, increasing drug resistance of tumor cells to such agents has led to demand for a better treatment approach like targeted PDCs and thereby, driving the peptide drug conjugates space.
Principal Consultant
Increasing Costs to Hinder Market Growth
Low bioactivity, poor stability, long research and development time, and slow clinical development process as therapeutic agents of PDC are expected to restrain the segment, leading to an increase in overall time and cost incurred for the development.
Presence of Key Players in the Region to Increase Consumer Demand
North America dominated the overall peptide drug conjugates (PDCs) market in terms of the revenue share of 45.6% in 2022, owing to the launch of Melflufen and the rapid uptake of PDC drugs in cancer therapy.
Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive market growth. Furthermore, rising cases of cancer and related mortality are fueling the market growth in the region. For instance, NCI reported approximately 1,806,590 new cancer cases and 606,520 disease-related deaths in 2020.
Increasing Investments to Develop PDCs to Boost Regional Market
Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period. The growth of the region is attributed to the upsurge in the number of cancer cases and strategic initiatives undertaken by the market players for regional expansion in such regions. Furthermore, rising research and development along with increasing investments to develop and commercialize such novel delivery systems is anticipated to boost the market growth in the region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Lutathera Product Segment to Dominate the Category
The Lutathera product segment dominated the peptide drug conjugates market with a revenue share of 80.5% in 2022. The first FDA-approved PDC is Novartis’s Lutathera (lutetium Lu 177), a radiolabeled somatostatin analog which is an advanced accelerator injection. The expected patent expiry date is 25th July 2038. It is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera consists of an amide linkage between homing peptide somatostatin and cytotoxic radiotherapeutic agent 177Lu.
Oncopeptides AB received FDA approval for its first-in-class peptide-conjugated alkylator, Pepaxto (melflufen), in February 2021. The combination of Pepaxto (Melphalan flufenamide) with dexamethasone is indicated for multiple myeloma in adult patients. The drug has demonstrated anti-myeloma activity in myeloma tumor cells resistant to bortezomib and the alkylator melphalan. Melflufen patents cover major markets in the USA, Japan, Canada, and Europe. However, the drug has been withdrawn from the USA market in October 2021, based on overall survival data from its phase 3 study.
Therapeutic Segment Leads the Type Segment and is Projected to Dominate the Market
Therapeutic agents of PDC dominated the peptide drug conjugates market with a revenue share of 82.3% in 2022 and are anticipated to witness the fastest growth. The factors attributing to dominance is the presence of both approved PDCs, Lutathera and Pepaxtoas therapeutic agents targeting tumor cells. Moreover, the presence of targeting therapeutic drugs such as ANG1005,
BT5528 and BT1718 under clinical trials are expected to boost the market during the forecast period. Along with cancer, pharmaceutical companies are developing targeting therapeutic PDCs for metabolic diseases and coronavirus diseases due to the significant benefits of PDCs in the therapeutic segment.
PDCs coupled with radionuclides can also act as diagnostic agents. For example, Mallinckrodt Pharmaceuticals’ In-DTPA-octreotide (octreoscan) which contains radioactive nucleotides, is primarily used in the localization of neuroendocrine tumors. Furthermore, the development and applications of PDCs in diagnosis are anticipated to offer remunerative opportunities for segment growth.
The players in the market are focusing to increase their global influence and adopt strategies such as; acquisition, collaboration, and partnerships. Key players in the market include Novartis AG; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Oncopeptides AB; Angiochem Inc.; Innovasium Soricimed Biopharma; and Theratechnologies. Some of the recent key developments among key players are:
| Report Attributes | Details |
|---|---|
| Market Value in 2023 | USD 861.12 Million |
| Market Value in 2033 | USD 5,331.83 Million |
| Forecast Period | 2023 to 2033 |
| Historical Data | 2018 to 2022 |
| Quantitative Units | USD Million for Value and CAGR from 2023 to 2033 |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Segments Covered | Type, Product, Region |
| Key Companies Profiled | Novartis AG; Oncopeptides AB; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Angiochem Inc.; Innovasium Soricimed Biopharma; Theratechnologies; Coherent Biopharma; WuXI STA |
| Pricing | Available upon Request |
North America will account for a major share of global Peptide Drug Conjugates demand.
From 2023 to 2033, the market is projected to expand at a 20% value CAGR, as per FMI.
By 2033, Peptide Drug Conjugates market demand is expected to reach USD 5,331.83 Million.
By 2023, demand for Peptide Drug Conjugates is forecast to be valued at USD 861.12 Million
As of 2022, the market for Peptide Drug Conjugates was valued at USD 717.6 Million
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Lutetium 5.2. Melflufen 5.3. ANG1005 5.4. BT1718 5.5. CBX-12 5.6. Other Pipeline Products 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 6.1. Therapeutic 6.2. Diagnostic 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Novartis AG 15.2. Oncopeptides AB 15.3. Bicycle Therapeutics 15.4. AstraZeneca 15.5. Cybrexa Therapeutics 15.6. Angiochem Inc. 15.7. Innovasium Soricimed Biopharma 15.8. Theratechnologies 15.9. Coherent Biopharma 15.10. WuXi STA 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Peptide Drug Conjugates Market
